No information is available on the clinical use of atezolizumab during breastfeeding. Because atezolizumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] Until more data become available, atezolizumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during atezolizumab therapy and for at least 5 months after the last dose.
关于阿替利珠单抗在母乳喂养期间的临床应用尚无可用信息。由于阿替利珠单抗是一种分子量为145,000道尔顿的大分子蛋白质，其在乳汁中的含量可能非常低，而且由于它可能在婴儿胃肠道中被破坏，因此不太可能被吸收。产后至少等待2周再恢复治疗可能会将药物转移至婴儿的情况降至最低。[1] 在有更多数据可用之前，母乳喂养期间应谨慎使用或避免使用阿替利珠单抗，尤其是在哺育新生儿或早产儿期间。制造商建议在阿替利珠单抗治疗期间及最后一剂后至少5个月内停止母乳喂养。
